SREBF1 and steatosis: These findings support others who have found similar hypoglycemic, hypolipidemic, insulin-improving, and anti-steatosis effects of γ-Oryzanol in sucrose, fructose, and HFD-fed rats, possibly due to their effect to reduce fecal lipid excretion (inhibiting intestinal lipase), inhibit gluconeogenesis enzymes (e.g., G6PD), and suppress lipogenic enzymes (e.g., malic enzyme, SREBP-1c, and fatty acid synthase) [40,50,51].